[Use of a new drug, lomefloxacin (maxaquin), from the fluoroquinolone group in the treatment of patients with wound infection].
A clinicolaboratory study on the efficacy of lomefloxacin (maxaquin, Searle, USA) was carried out in the treatment of 31 patients with wound infections. In the complex therapy the clinical efficacy of the drug amounted to 96.7 per cent and its bacteriological activity reached 64.6 per cent. The drug tolerance in the majority of the cases was good. Only in one patient an allergic reaction in the form of multiple skin eruption on the 6th day of the treatment was recorded. One patient showed an insignificant increase in the level of alanine aminotransferase not accompanied by any signs of hepatic insufficiency.
Blatun
L A
LA
Grishina
I A
IA
Svetukhin
A M
AM
Iakovlev
V P
VP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D014946:Wound Infection / Q000188:drug therapy*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C053091:lomefloxacin
Primenenie novogo preparata iz gruppy ftorkhinolonov lomefloksatsina (maksakvina) pri lechenii bol'nykh s ranevoĭ infektsieĭ.